ArticleBulletin of experimental biology and medicine2025
Mycoplasma hominis as an Infectious Agent of the Human Prostate Carcinoma Cell Line LNCaP.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previously, a link between mycoplasmas and the development of malignant neoplasms, particularly prostate cancer, had been shown. However, the mechanisms responsible for the oncogenic properties of mycoplasmas remain poorly understood. We have developed an infectious model of LNCaP prostate lymph node carcinoma cell line infection with Mycoplasma hominis (MHO). It has been shown that MHO can easily attach and invade into cells without reducing the growth rate or affecting morphology of LNCaP cells. Proteomic analysis has shown that during infection, MHO undergoes a significant functional restructuring decelerating its growth and leading to formation of mini colonies. This reorganization is associated with a shift in energy metabolism a less energy-efficient nucleoside utilization pathway. To adapt within LNCaP, MHO changes its repertoire of membrane proteins, variable antigens involved in adhesion and protection from host immunity. It is hypothesized that the transcription factor YebC plays a role in MHO survival within the eukaryotic cell.
Indexed as
Identifiers
40299130What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.